<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12823">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02939989</url>
  </required_header>
  <id_info>
    <org_study_id>M15-942</org_study_id>
    <secondary_id>2016-002491-26</secondary_id>
    <nct_id>NCT02939989</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study</brief_title>
  <acronym>MAGELLAN-3</acronym>
  <official_title>An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination With Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies (MAGELLAN-3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of co-administration of
      ABT-493/ABT-530 plus sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV)
      genotype (GT) 1 - 6-infected participants (including non-cirrhotic, or cirrhotic
      participants) who have experienced virologic failure in an AbbVie parent clinical study.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with sustained virologic response 12 weeks post dosing (SVR12)</measure>
    <time_frame>12 weeks after last dose of study drug</time_frame>
    <description>Percentage of participants with hepatitis C virus ribonucleic acid less than the lower limit of quantitation (LLOQ) (less than 15 IU/mL) 12 weeks after the last actual dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with on-treatment virologic failure.</measure>
    <time_frame>Treatment Day 1 to end of treatment (up to 12 or 16 weeks depending on treatment arm)</time_frame>
    <description>On treatment virologic failure is defined as confirmed increase from nadir in HCV RNA (defined as 2 consecutive HCV RNA measurement of &gt; 1 log10 IU/mL above nadir) at any time point during treatment; or confirmed HCV RNA ≥ 100 IU/mL (defined as 2 consecutive HCV RNA measurements ≥ 100 IU/mL) after HCV RNA &lt; LLOQ during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with post-treatment HCV virologic relapse</measure>
    <time_frame>Up to 24 weeks after last dose of study drug</time_frame>
    <description>Percentage of participants with confirmed quantifiable HCV RNA after completion of treatment among participants with unquantifiable HCV RNA at the end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hepatitis C Virus Infection</condition>
  <arm_group>
    <arm_group_label>ABT-493/ABT-530 + SOF + RBV for 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493/ABT-530 (300/120 mg) QD + SOF (400 mg) QD + weight-based RBV (1000 - 1200 mg) twice daily (BID) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493/ABT-530 + SOF + RBV for 16 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493/ABT-530 (300/120 mg) QD + SOF (400 mg) QD + weight-based RBV (1000 - 1200 mg) BID for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-493/ABT-530</intervention_name>
    <description>Tablet</description>
    <arm_group_label>ABT-493/ABT-530 + SOF + RBV for 12 weeks</arm_group_label>
    <arm_group_label>ABT-493/ABT-530 + SOF + RBV for 16 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>Tablet</description>
    <arm_group_label>ABT-493/ABT-530 + SOF + RBV for 12 weeks</arm_group_label>
    <arm_group_label>ABT-493/ABT-530 + SOF + RBV for 16 weeks</arm_group_label>
    <other_name>SOVALDI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Tablet</description>
    <arm_group_label>ABT-493/ABT-530 + SOF + RBV for 12 weeks</arm_group_label>
    <arm_group_label>ABT-493/ABT-530 + SOF + RBV for 16 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Participants who experienced virologic failure during or after
        treatment with ABT 493/ABT-530 in an AbbVie hepatitis C virus (HCV) parent study.
        Participants who have experienced virologic failure during or after receiving
        ombitasvir/paritaprevir/r + dasabuvir (3D), ombitasvir/paritaprevir/r (2D) in AbbVie HCV
        parent study may be enrolled at AbbVie's discretion.

          -  Cirrhotic participants must have compensated cirrhosis, (Child-Pugh score of less
             than or equal to 6) at screening and no current or past evidence of Child-Pugh B or C
             Classification or no clinical history of liver decompensation, including ascites
             noted on physical exam, hepatic encephalopathy or esophageal variceal bleeding.

          -  Cirrhotic participants must have absence of hepatocellular carcinoma (HCC) as
             indicated by a negative ultrasound (US), computed tomography (CT) scan or magnetic
             resonance imaging (MRI) within 3 months prior to Screening or a negative US at
             Screening.

        Exclusion Criteria: - History of severe, life-threatening or other significant sensitivity
        to any study drug or drug component.

          -  Female participant who is pregnant, breastfeeding or is considering becoming pregnant
             during the study or for 4 months after the last dose of study drug, or as directed
             per the local ribavirin label.

          -  Recent (within 6 months prior to study drug administration) history of drug or
             alcohol abuse that could preclude adherence to the protocol in the opinion of the
             investigator, and failure in an AbbVie HCV parent study due to non-virologic reasons.

          -  Positive test result at screening for hepatitis B surface antigen (HBsAg).

          -  Screening laboratory analyses showing creatinine clearance less than 30 mg/dL.

          -  Discontinuation from previous AbbVie HCV clinical studies for reasons other than
             virologic failure (e.g., non-adherence, lost to follow-up, and/or the occurrence of
             an adverse event).

          -  Receipt of any HCV treatment after failing the treatment regimen in the AbbVie HCV
             parent study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Betty Yao, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155719</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155714</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155713</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155720</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155721</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155731</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155729</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 157881</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155715</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155727</name>
      <address>
        <city>Parkville</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155591</name>
      <address>
        <city>Dunedin</city>
        <zip>9016</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 19, 2017</lastchanged_date>
  <firstreceived_date>October 19, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Virologic failure</keyword>
  <keyword>Compensated Cirrhosis</keyword>
  <keyword>HCV Genotype 3 (HCV GT3)</keyword>
  <keyword>HCV Genotype 5 (HCV GT5)</keyword>
  <keyword>Chronic Hepatitis C (HCV)</keyword>
  <keyword>HCV Genotype 4 (HCV GT4)</keyword>
  <keyword>HCV Genotype 2 (HCV GT2)</keyword>
  <keyword>HCV Genotype 1 (HCV GT1)</keyword>
  <keyword>HCV Genotype 6 (HCV GT6)</keyword>
  <keyword>Non-cirrhotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
